A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes

Hirotake Tokuyama; Harukiyo Kawamura; Masaki Fujimoto; Kazuki Kobayashi; Mie Nieda; Tetsuya Okazawa; Minoru Takemoto; Fumio Shimada

doi:10.1016/j.diabres.2013.03.034

A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes

Diabetes Res Clin Pract. 2013 Jun;100(3):e66-9. doi: 10.1016/j.diabres.2013.03.034. Epub 2013 Apr 22.

Authors

Hirotake Tokuyama¹, Harukiyo Kawamura, Masaki Fujimoto, Kazuki Kobayashi, Mie Nieda, Tetsuya Okazawa, Minoru Takemoto, Fumio Shimada

Affiliation

¹ Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. hiroppy_hiroppy@yahoo.co.jp

PMID: 23618553
DOI: 10.1016/j.diabres.2013.03.034

Abstract

A potential adverse effect of dipeptidyl peptidase-4 inhibitors (DPP-4i) on the pancreas remains controversial. We evaluated the DPP-4i effects on pancreatic amylase and lipase activity in patients with type 2 diabetes. These enzymes were slightly but significantly increased, suggesting DPP-4i cause a low-grade inflammatory change in the exocrine pancreas.

MeSH terms

Aged
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy
Diabetes Mellitus, Type 2 / enzymology*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Female
Humans
Lipase / blood
Male
Middle Aged
Pancreas / drug effects
Pancreas / enzymology
Pancreatic alpha-Amylases / blood
Pancreatitis / blood
Retrospective Studies

Substances

Dipeptidyl-Peptidase IV Inhibitors
Lipase
Pancreatic alpha-Amylases